研究单位：[1]MediLink Therapeutics (Suzhou) Co., Ltd.[2]Anhui Tumour Hospital,Hefei,Anhui,China[3]The first affiliated hospital of Anhui Medical University,Hefei,Anhui,China[4]Beijing Cancer hospital,Beijing,Beijing,China[5]Peking University Third Hospital,Beijing,Beijing,China[6]Chongqing University Affiliated Tumor Hospital,Chongqing,Chongqing,China[7]The first affiliated hospital of Chongqing Medical University,Chongqing,Chongqing,China[8]The Second Affiliated Hospital of Chongqing Medical University,Chongqing,Chongqing,China[9]Xinqiao Hospital of AMU,Chongqing,Chongqing,China[10]Fujian Tumor Hospital,Fuzhou,Fujian,China[11]The First Affiliated Hospital of Sun Yat-sen University,Guangzhou,Guangdong,China[12]The Sixth Affiliated Hospital of Sun Yat-Sen University,Guangzhou,Guangdong,China[13]Shantou University Medical College Tumour Hospital,Shantou,Guangdong,China[14]Guangxi Medical University Affiliated Tumour Hospital,Nanning,Guangxi,China[15]The People''s Hospital of Guangxi,Nanning,Guangxi,China[16]Harbin Medical university cancer hospital,Harbin,Heilongjiang,China[17]Xinxiang Medical University No.1 Affiliated Hospital,Xinxiang,Henan,China[18]He''nan Cancer Hospital South Gate,Zhengzhou,Henan,China[19]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China[20]The First Peoples Hospital of Jingzhou,Jingzhou,Hubei,China[21]Hubei Cancer Hospital,Wuhan,Hubei,China[22]Tongji Hospital,Wuhan,Hubei,China[23]Union Hospital, Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei,China[24]Xiangyang Central Hospital,Xiangyang,Hubei,China[25]Hu''nan Province Cancer Hospital,Changsha,Hunan,China[26]Xiangya hospital Central South University,Changsha,Hunan,China[27]The Second Affiliated Hospital of Soochow University,Suzhou,Jiangsu,China[28]Xuzhou Central Hospital,Xuzhou,Jiangsu,China[29]First Affiliated Hospital of Gannan Medical University,Ganzhou,Jiangxi,China[30]Jiangxi Cancer Hospital,Nanchang,Jiangxi,China[31]The Third Hospital of Nanchang,Nanchang,Jiangxi,China[32]Jilin Provincial Cancer Hospital,Changchun,Jilin,China,215000[33]China-Japan Union Hospital of Jilin University,Changchun,Jilin,China[34]The second Hospital of Dalian Medical University,Dalian,Liaoning,China[35]Liaoning Cancer Hospital & Institute,Shenyang,Liaoning,China[36]The First Hospital of China Medical University Physical Examination Center,Shenyang,Liaoning,China[37]Shandong Cancer Hospital,Jinan,Shandong,China,250117[38]Jinan Central Hospital Affiliated to Shandong University,Jinan,Shandong,China[39]Shandong Cancer Hospital,Jinan,Shandong,China[40]Affiliated Hospital of Jining Medical University,Jining,Shandong,China[41]Linyi Cancer hospital,Linyi,Shandong,China[42]The Affiliated Hospital of Qingdao University,Qingdao,Shandong,China[43]Weifang People''s Hospital,Weifang,Shandong,China[44]Huashan Hospital affiliated to Fudan University,Shanghai,Shanghai,China[45]Shanghai General Hospital,Shanghai,Shanghai,China[46]Shanghai Ninth People''s Hospital,Shanghai,Shanghai,China[47]The No.10 Peoples Hospital,Shanghai,Shanghai,China[48]Sichuan Cancer Hospital,Chengdu,Sichuan,China[49]West China Hospital of Sichuan University,Chengdu,Sichuan,China[50]Yunnan Tumor Hospital,Kunming,Yunnan,China[51]The Second Affiliated Hospital of Zhejiang University school of Medicine,Hangzhou,Zhejiang,China[52]Zhejiang University Medical College Affiliated No.1 Hospital,Hangzhou,Zhejiang,China[53]Yiwu Central Hospital,Jinhua,Zhejiang,China[54]Taizhou Hospital of Zhejiang,Taizhou,Zhejiang,China
This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in the following selected patients with advanced solid tumors.
